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INTRODUCTION
The cellular responses that follow the administra-
tion of interferons (IFNs) in vivo are very complex
and difficult to unravel. Under some experimental
conditions, IFNs stimulate different kinds of cells and
cause up-regulation of expression of antigens and
production of cytokines (1-7). Moreover, IFN-α and
IFN-γ, administered simultaneously, act synergistically
(8-10).This results in very elaborate and intricately
related actions between carcinoma cells, endothelium,
lymphocytes, and macrophages, which ultimately
may lead to the destruction of tumor cells. IFN-α
and IFN-γ augment LAK activity developed from
PBMNCs of healthy volunteers (11-14). LAK cells
alone, IL-2alone, or LAK cells plus IL-2 are used for
cancer treatment and achieve regression of cancer
(15, 16). It is the purpose of this study to draw an
outline of the cellular events in breast cancer patients
treated with IFN-α/IFN-γ and IL-2.
MATERIALS AND METHODS
Materials
The subjects were 7 pre-operative patients with
resectable primary breast cancer and 4 healthy vol-
unteers. Cancer cells of 6 of 7 pre-operative patients
were positive in the estrogen receptor.
Reagents
Recombinant IL-2 was prepared by Takeda Pharma-
ceutical Co. (Osaka, Japan), and had a specific activity
of 3.5x104 mU/mg as assayed using IL-2-dependent
murine NKC 3 cells (17).
Cell Line
Human Burkitt lymphoma cells (Daudi) and estro-
gen receptor positive human breast cancer cells
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(MCF-7) were maintained as stationary suspension
cultures in RPMI 1640 medium supplemented with
10% heat-inactivated FBS and gentamicin at 37℃
in a humidified atmosphere of 5% CO2 in air. MCF-7
cells were kindly provided by Otsuka Pharmaceutical
Co. (Japan).
Isolation and culture of PBMNCs
MNCs were separated from the peripheral blood by
discontinuous gradient centrifugation in lymphocyte
separation medium (18, 19).
Assay of LAK activities and cytotoxicity against MCF-7
LAK activity and cytotoxicity against MCF-7 were
assayed by measuring 51Cr release using a method
described previously (18, 19). Briefly, PBMNCswere
incubated with or without serial concentrations
of IFN-α, IFN-γ or IL-2 (400U/ml) for 4 days in
RPMI 1640 medium supplemented with 5% FBS and
gentamicin at 37℃ under 5% CO2 in humidified air.
Unless otherwise noted, 400 U/ml of IL-2 was used
for development of LAK activity in PBMNCs ; we
confirmed that these concentrations of IL-2 were opti-
mal for development of LAK activity from PBMNCs.
There was no significant difference between the
number of cells after four days of culture with or
without IFN-α, IFN-γ, or IL-2. The cytotoxicity of
cultured PBMNCs against 51Cr-labeled Daudi cells
(1x104) was measured at a 10 : 1 effector : target (E/T)
cell ratio in triplicate cultures. And the cytotoxicity
of cultured PBMNCs against 51Cr-labeled MCF-7
(1 x 104) was measured at 10 : 1, 20 : 1, and 40 : 1
E/T cell ratios in triplicate cultures. Coculture of
effector cells and target cells was terminated after
4h, and the radioactivity of the supernatants (0.1ml
per well), separated by brief centrifugation at 65 x g
was determined using a gamma counter. The percent
cytotoxicity was calculated as follows :
experimental cpm－spontaneous cpm% cytotoxicity = %total cpm－spontaneous cpm
Spontaneous cpm was about 10% (range : 7 to 13%)
of total cpm. Total cpm was determined from the
radioactivity in the supernatant of Daudi cells (1 x
104) or MCF-7 (1 x 104) after lysis with 2 N HCl.
Statistical Analysis
The significance of differences between groups
was determined using the paired or non paired t-test
for 2 corresponding groups.
RESULTS
Effect of IFN-α on development of LAK activity by
IL-2 from PBMNCs
Significant LAK activity was developed from
PBMNCs of pre-operative breast cancer patients
and healthy volunteers after incubation for 4 days
with IL-2 (presence of IL-2 vs. absence of IL-2, p<
0.01 (data not shown)). Stimulation with 1000U/ml
of IFN-α significantly suppressed the LAK activity of
PBMNCs from pre-operative breast cancer patients
by IL-2 (P<0.05) (Figure 1). But stimulation with
IFN-α showed no change in the LAK activity of
PBMNCs from healthy volunteers.
Effect of IFN-γ on development of LAK activity by
IL-2 from PBMNCs
Stimulation with 1000 U/ml of IFN-γ signifi-
cantly augmented LAK activity of PBMNCs from
pre-operative breast cancer patients by IL-2 (P<0.05)
(Figure2). On the other hand, stimulation with IFN-γ
did not change the LAK activity developed from
PBMNCs of healthy volunteers.
Development of cytotoxicity against MCF-7by IL-2
from PBMNCs
Significant cytotoxicity against MCF-7 was exhibited
Fig.1. Effect of IFN-α on development of LAK activity by IL-2
from PBMNCs.
PBMNCs (105) from 4 healthy volunteers (○) and 5 pre-operative
breast cancer patients (●) were incubated for 4 days with
IL-2 (400U/ml) and serial concentrations of IFN-α varying from
0 to 1000U/ml in 96-well plastic plates. % cytotoxicity was
determined as described in the text. The bars represent the mean
percentage of cytotoxicity against an allogeneic cell line of Daudi
cells at a 10 : 1 effector : target ratio.
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by PBMNCs from pre-operative breast cancer patients
at 20 : 1 and 40 : 1 E/T ratios after incubation for 4
days with IL-2 (absence of IL-2 vs. 20 : 1 or 40 : 1,
P<0.05, P<0.05) (Figure 3). PBMNCs of healthy
volunteers did not develop cytotoxicity against MCF-7
after incubation for 4 days with IL-2 at serial E/T
ratios (data not shown).
Effect of stimulation with IFN-α or IFN-γ on devel-
opment of cytotoxicity against MCF-7 from PBMNCs
of pre-operative breast cancer patients
Stimulation with 1000 U/ml of IFN-γ significantly
augmented cytotoxicity against MCF-7 developed
from PBMNCs from pre-operative breast cancer
patients by IL-2 at a 40 : 1 E/T ratio (P<0.05) (Figure 4).
By contrast, stimulation with 1000 U/ml of IFN-α
significantly suppressed cytotoxicity against MCF-7
developed from PBMNCs from pre-operative breast
cancer patients by IL-2 at a 40 : 1 E/T ratio (P<0.05)
(Figure 4).
DISCUSSION
In the present study, we examined whether IFN-α
or IFN-γ augment LAK activity and cytotoxicity against
MCF-7m of PBMNCs from pre-operative breast cancer
patients and healthy volunteers by IL-2. PBMNCs
from healthy volunteers developed significant LAK
activity but these cells did not show significant
cytotoxicity against MCF-7 at a 10 : 1, 20 : 1, or 40 : 1
E/T ratio. Peripheral blood lymphocytes migrate
into tumor and may play a role as tumor infiltrating
Fig.２. Effect of stimulation with IFN- γ on development of LAK
activity by IL-2 from PBMNCs.
PBMNCs (105) from 4 healthy volunteers (○) and 7 pre-operative
breast cancer patients (●) were incubated for 4 days with IL-2
and serial concentrations of IFN-γ varying from 0 to 1000 U/ml
in 96-well plastic plates before LAK assay. % cytotoxicity was
determined as described in the text. The bars represent the
mean percentage of cytotoxicity against an allogeneic cell line
of Daudi cells at a 10 : 1 effector : target ratio.
Fig.３. Development of cytotoxicity against MCF-7 by IL-2 from
PBMNCs. Various numbers (1 x 105, 2 x 105, 4 x 105) of freshly
separated PBMNCs from 7 pre-operative breast cancer patients
were incubated for 4 days with IL-2 in 96-well plastic plates before
assay. Then the % cytotoxicity was determined. Results represent
the mean±SD.
Fig.４. Effect of stimulation with IFN-γ and α on development
of cytotoxicity by IL-2 from PBMNCs of pre-operative breast
cancer patients against MCF-7.
PBMNCs (105) from 7 pre-operative breast cancer patients were
incubated for 4 days with IL-2 and/or 1000U/ml of IFN-γ or
1000 U/ml of IFN-α in 96-well plastic plates before LAK assay.
% cytotoxicity was determined as described in the text. The bars
represent the mean percentage of cytotoxicity against an allogeneic
cell line of MCF-7 cells at a 40 : 1 effector : target ratio.
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lymphocytes (TIL) (20). Indeed, TIL in breast cancer
may be important to immunological defense (21).
And the roles of TIL may relate to improved prognosis
and survival in breast cancer patients (22, 23). It is,
therefore, important to activate peripheral lympho-
cytes in breast cancer patients to develop cytotoxicity
against breast cancer cell. As previously reported
(24), PBMNCs from breast cancer patients in the
present study developed significant LAK activity. More-
over, PBMNCs separated from pre-operative breast
cancer patients developed significant cytotoxicity
against MCF-7, whereas PBMNCs from healthy vol-
unteers did not. Cell-mediated immunity is suppressed
to a much greater extent in some cancer patients (25).
But PBMNCs in pre-operative breast cancer patients
have been already activated to develop significant
cytotoxicity against breast cancer cells. Biological
characteristics of breast cancer cells may induce the
immunological activation of PBMNCs in pre-operative
breast cancer patients as previously reported (26).
The efficient LAK activity might improve the prog-
nosis and survival of cancer patients (27, 28). Breast
cancer patients have been reported to have a better
prognosis than patients with other malignancies (29,
30). One reason for the good prognosis of breast
cancer patients might be the activated state of
lymphocytes. IFN-γ augments LAK activity from
PBMNCs of breast cancer patients (23). In our study,
IFN-γ augmented not only LAK activity from PBMNCs
of pre-operative patients but also cytotoxicity against
breast cancer cells. In contrast, IFN-α significantly
suppressed this activity. Although IFN-α and γ have
antiproliferative effects on human breast cancer cells
in culture (31-34), IFN-α suppressed LAK activity
and cytotoxicity against MCF-7.
These results indicated that the induction of
cytotoxicity from lymphocyte by a combination of
IFN-γ and IL-2 may be helpful in designing more
effective cancer immunotherapeutic protocols for
breast cancer patients.
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